Skip to main content
CancerCAR T Cell TherapyImmunotherapy

Ep. 4: “Therapeutic T Cell Engineering” Featuring Drs. Carl June and Philipp Rommel

By May 11, 2021January 9th, 2023No Comments

Dr. Carl June and Dr. Philipp Rommel


Dr. Carl June is the Richard W. Vague Professor in Immunology at the University of Pennsylvania, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy. Dr. Philipp Rommel is a Postdoctoral Researcher in the June lab. Together, they are interested in lymphocyte biology, with a major translational focus on ex vivo T cell engineering for cancer and HIV cell-based therapies.

Featured Products and Resources:

The Immunology Science Round Up

Pooled CRISPR Screening Identifies m6A RNA as a Regulator of Macrophage Activation – Scientists identified METTL3-mediated m6A modification in innate immune responses suggesting the m6A machinery could be a target for immunotherapy.

Natural Killer Receptors Fine-Tune T Cells – Researchers identified a role for natural killer cell receptor signaling in regulating self/non-self discrimination by HLA-E–restricted T cells.

Notch4 Signaling in Viral Infections – Notch4 expression on Treg cells suppressed the induction of amphiregulin and promoted severe lung inflammation in viral infections.

Synthetic Notch CAR T Cells Targeting Solid Tumors in Mice – Scientists developed synthetic Notch CAR T cells targeting solid tumor antigens and used them to treat mouse models of mesothelioma, ovarian cancer, and glioblastoma.

Photo Reference: Courtesy of Drs. Carl June and Philipp Rommel

Subscribe to our newsletter!

Never miss updates about new episodes.